Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

NCT07517198 is registered in ClinicalTrials.gov with Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07517198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07517198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 13, 2026
Completion date
March 31, 2029
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, head and neck squamous cell carcinoma (hnscc), hepatic cancer, high grade neuroendocrine cancer, non-small cell lung cancer (nsclc), ovarian cancer, prostate cancer, renal carcinoma (clear and non-clear cell), small cell carcinomas of non-lung origin, small cell lung cancer (sclc), solid tumor, triple-negative breast cancer (tnbc)